[1]近藤照義,吉武重徳, “第 2 章 腎臓・尿路系の構造と機能,” 臨床工学講座 生体機能代行装置学,東京,医歯薬出版株式会社, pp. 7-16, 2018.
[2] 篠田俊雄, “第 4 章 腎疾患と病態生理,”臨床工学講座 生体機能代行装置学,東京,医歯薬出版株式会社, pp. 29-38, 2015.
[3] T. Yamaka, “Biocompatibility of the new anticoagulant dialyzer TORAYLIGHT ® NV,” Science Postprint, 2014.
[4]日本透析医学会, “2017年末の慢性透析患者に関する集計,” 2017. Available: https://docs.jsdt.or.jp/overview/file/2017/pdf/1.pdf. [アクセス日: 7 May 2019].
[5]小久保謙一, “第 5 章 血液透析の原理と構成,”臨床工学講座 生体機能代行装置学,東京,医歯薬出版株式会社, pp. 39-50, 2018.
[6]小野淳一, “第 10 章 持続的血液浄化療法,”臨床工学講座 生体機能代行装置学,東京,医歯薬出版株式会社, pp. 203-216, 2018.
[7]小澤英俊, “Cytokine-adsorbing hemofilter東レ「ヘモフィールCH-1.8W」の特徴と機能,”人工臓器, 43, pp. 228-232, 2014.
[8]塚本功,村杉浩, 秋元照美,土持多美恵,仲松晋也,山下芳久,正田純子, 菅原壮一,鈴木洋通, “CHDF施行時におけるhemofilterの凝固系への影響,” ICUとCCU, 32, pp. S128-S132, 2008.
[9] 福田誠, “第 5 章 透析膜,” 臨床工学講座 生体機能代行装置学,東京,医歯薬出版株式会社, pp. 51-71, 2018.
[10]日本透析医学会, “2017年末の慢性透析患者に関する集計,” 2017. [オンライン]. Available: https://docs.jsdt.or.jp/overview/file/2017/pdf/5.pdf. [アクセス日: 18 Jul 2019].
[11] NA. Hoenich, C. Woffindin, JN. Mathews, J. Vienken, "Biocompatibility of membranes used in the treatment of renal failure," Biomaterials, 8, pp. 587- 592, 1995.
[12] T. Sunohara, T. Masuda, "Cellulose Triacetate as a High-Performance Membrane," Contrib Nephrol, 173, pp. 156-163, 2011.
[13]櫻井秀彦, 鈴木充, “透析膜；透析膜の種類と特徴：CTA (cellulose triacetate)膜,”わかりやすい透析工学,東京,南江堂, pp. 33-36, 2012.
[14] 中林宣男, “5 生体適合材料の機能と応用 血液浄化材料 血液透析膜,” 生体適合材料,東京,日本規格協会, pp. 139, 1993.
[15] 福田誠, “Ⅲ 透析膜 ②透析膜の種類と特徴 PS (Polysulfone)膜,”わかりやすい透析工学,東京,南江堂, pp. 53-61, 2015.
[16]板垣一郎, “透析膜；透析膜の種類と特徴：PS (Polysulfone),”わかりやすい透析工学,東京,南江堂, pp. 47-52, 2012.
[17] N. Ochoa, P. Pradanos, L. Palacio, C. Pagliero, J. Marchese, A. Hernandez, “Pore size distributions based on AFM imaging and retention of multidisperse polymer solutes: characterisation of polyethersulfone UF membranes with dopes containing different PVP,” J Memb Sci, 187, pp. 227-237, 2001.
[18] M. Matsuda, K. Yamamoto, T. Yakushiji, “Nanotechnological evaluation of protein adsorption on dialysis membrane surface hydrophilized with polyvinylpyrrolidone,” J Memb Sci, 310, pp. 219-228, 2008.
[19] K. Namekawa, M. Fukuda, M. Matsuda, Y. Yagi, K. Yamamoto, K. Sakai, “Nanotechnological characterization of human serum albumin adsorption on wet synthetic polymer dialysis membrane surfaces,” ASAIO J, 55, pp. 236-242, 2009.
[20] 食品安全委員会 添加物専門調査会, “添加物評価書,” 9 2006. Available: https://www.fsc.go.jp/fsciis/attachedFile/download?retrievalId=kai20060913te1 &fileId=108. [アクセス日: 29 11 2019].
[21]根岸直樹, 野崎幹弘, “材料に対する生体の免疫応答,”バイオマテリアルと生体-副作用と安全性,東京, 中山書店, pp. 478-500, 1998.
[22] AC. Yamashita, N. Tomisawa, A. Takezawa, K. Sakurai, T. Sakai, “Blood compatibility and filtration characteristics of a newly developed polyester polymer alloy membrane,” Hemodialysis International, 8, pp. 368-371, 2004.
[23]宮田賢宏, 陶山実有希,海本浩一, “ポリビニルピロリドン溶出に対するビタミンEコーティングポリスルホン膜ダイアライザの有用性,” 生体医工学, 50, pp. 700- 705, 2012.
[24] K. Namekawa, A. Kaneko, K. Sakai, S. Kunikata, Matsuda, “Longer storage of dialyzers increases elution of poly(N-vinyl-2-pyrrolidone) from polysulfone- group dialysis membranes,” J Artif Organs, 14, pp. 52-57, 2011.
[25]板垣一郎, “Ⅲ透析膜/②透析膜の種類と特徴 PMMA (polymethylmethacrylate),”わかりやすい透析工学 血液浄化療法の化学的基礎,東京,南江堂, pp. 42-46, 2015.
[26]氏平政伸, “第 8 章 医療材料に求められる条件とは,”臨床工学講座 生体物性・医用材料工学,東京,医歯薬出版株式会社, pp. 139-148, 2017.
[27]斎藤明, “ダイアライザーと滅菌,”人工臓器, 18, pp. 1618-1625, 1989.
[28] 一般社団法人日本医療機器学会, “医療現場における滅菌保証のガイドライン2015,” Available: http://www.jsmi.gr.jp/wp- content/uploads/2015/07/Guideline2015ver3.pdf. [アクセス日: 13 11 2019].
[29] JR. Beall, “Formaldehyde in dialysis patients. Formaldehyde Analytical Chemistry and Toxicology,” Chapter 19;275, Washington DC, American Chemical Society, 1985.
[30]宇佐美光司,森川実,大井一正, “酸化エチレンガス滅菌,” 著:医療現場の滅菌,東京,へるす出版, pp. 24-41, 2005.
[31] 田中悟, “エチレンオキサイドの溶血性および皮膚刺激性について,”医学器, 57, 21, pp. 21-28, 1981.
[32] 高橋幸雄, “長期血液透析患者にみられる著しい好酸球増多症について,”日腎誌, 21, 959, pp. 959-974, 1979.
[33] 田中和義, “高圧蒸気滅菌,”医療現場の滅菌,東京,へるす出版, pp. 5-23, 2005.
[34] 高木豊己,山中直樹,斎藤明,太田和宏, “高圧蒸気滅菌及びガンマー線滅菌各種ダイアライザーの性能評価,”人工臓器, 10, pp. 268-270, 1981.
[35] 赤阪郁弥,山下明泰, “透析膜の滅菌法および物理化学的構造が溶質の透過特性に及ぼす影響,”法政大学大学院理工学・工学研究科紀要, 57, pp. 1-2, 2016.
[36] 荘野忠泰, 稲垣王子, 竹中義昭, 長坂肇,平林俊明,森頴太郎, 井上聖士, 藤田嘉一,申曽洙,宮本孝, “透析器滅菌法の臨床評価,”人工臓器, 18, pp. 1191-1194, 1989.
[37]島津秀明, “MEの基礎となる生体物性,” MEの基礎知識と安全管理,東京,南江堂, pp. 43-62, 2018.
[38]住重アテックス株式会社, “電子線滅菌の性質、原理、ほかの滅菌法との比較,” Available: https://www.shi-atex.com/service/radiation/ebsterilization02.php. [アクセス日: 13 11 2019].
[39]国立行政法人放射線医学総合研究所, “放射線被爆,” Available: http://www.nirs.go.jp/qa/html/index.html. [アクセス日: 13 11 2019].
[40]土田健司, “透析技術；抗凝固薬,”臨床工学講座 生体機能代行装置学 血液浄化療法装置,東京,医歯薬出版株式会社, pp. 88-92, 2018.
[41] T. Tomo, “Biocompatibility of Hemodiafilters,” Contrib Nephrol, 189, pp. 210- 214, 2017.
[42] L. Pieroni, S. Levi Mortera, V. Greco, V. Sirolli, M. Ronci, P. Felaco, G. Fucci, “Biocompatibility assessment of haemodialysis membrane materials by proteomic investigations,” Mol Biosyst, 11, pp. 1633-1643, 2015.
[43] T. Kiefer, R. Becker, “Inhibitors of platelet adhesion,” Circulation, 120, pp. 2488-2495, 2009.
[44] F. Olafiranye, W. Kyaw, O. Olafiranye, “Resolution of dialyzer membrane- associated thrombocytopenia with use of cellulose triacetate membrane: a case report,” Case Report Med, 134295, 2011.
[45] J. Han, K. Park, M. Lee, C. Kim, H. Koo, F. Doh, E. Kim, J. Han, S. Han, T. Yoo, S. Kang, H. Oh, “Mean platelet volume is a prognostic factor in patients with acute kidney injury requiring continuous renal replacement therapy,” J Crit Care, 29, pp. 1016-1021, 2014.
[46] J. Li, D. Sheng, D. Cheng, F. Wang, G. Jian, Y. Li, T. Xu, X. Wang, Y. Fan, N. Wang, “Is the mean platelet volume a predictive marker of a high in-hospital mortality of acute cardiorenal syndrome patients receiving continuous renal replacement therapy?,” Medicine, 97, pp. e11180, 2018.
[47] M. Kiali, O. Djurdjev, M. Farah, A. Levin, B. Jung, J. MacRae, “Use of Electron-Beam Sterilized Hemodialysis Membranes and Risk of Thrombocytopenia,” JAMA, 306, pp. 1679-87, 2011.
[48]川西秀樹, “特別な機能をもつ血液透析器の特徴と評価法A1)透析膜の生体適合性,” 透析会誌, 50, pp. 363-399, 2017.
[49]政金生人, “特別な機能をもつ血液透析器の特徴と評価法A3)生体適合性：臨床評価マーカー,” 透析会誌, 50, pp. 379-383, 2017.
[50] S. Itoh, “Platelet activation through interaction with hemodialysis membranes induces neutrophils to produce reactive oxygen species,” J Biomed Mater Res A, 77, pp. 294-303, 2006.
[51] K. Kokubo, Y. Kurihara, K. Kobayashi, H. Tsukao, H. Kobayashi, “Evaluation of the Biocompatibility of Dialysis Membranes,” Blood Purif, 40, pp. 293-297, 2015.
[52] D. Sakvemini, G. de Nucci, JM. Sneddon, JR. Vane, “Superoxide anions enhance platelet adhesion and aggregation,” Br J Phamacol, 97, pp. 1145-50, 1989.
[53]坂爪公, 齊木佳克, “人工循環中の出血凝固因子,”人工臓器, 45, 3, pp. 221-224, 2016.
[54]平方秀男, “血小板活性化,” 著:日常診療に役立つ 血小板・血液凝固線溶と周術期管理,東京, 真興交易（株）医書出版部, pp. 37-49, 2004.
[55] 野村昌作, “血小板活性化マーカー,” 血栓止血誌, 18, pp. 597-606, 2007.
[56] J. Daugirdas, A. Bernardo, “Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia,” kidney Int, 82, pp. 147-157, 2012.
[57] I. Uhlenbusch-Korwer, “Biocompatibility characteristics of dialyzers and hemofilters,” Understanding Membranes and Dialysers, Lengerich, Germany, Pabst Science Publishers, pp. 265-266, 2004.
[58] 芝本隆, “Dialyzerの生体適合性評価指標としてのbeta-thromboglobulinにかんする検討,”人工臓器, 10, pp. 98-101, 1981.
[59] R. Frank, J. Weber, H. Dresbach, H. Thelen, C. Weiss, J. Floege, “Role of contact system activation in hemodialyzer-induced thrombogenicity,” Kidney Int, 60, pp. 1972-1981, 2001.
[60] J. Post, “Thrombocytopenia associated with use of a biocompatible hemodialysis membrane: a case report,” Am J Kidney Dis, 55, pp. 25-28, 2010.
[61] 甲田豊, “10 章 HDFと生体適合性,” HDF 療法ハンドブック,東京,南江堂, pp. 99-109, 2000.
[62]川西秀樹, “1 生体適合性とは Ⅰ 透析膜との接触による反応,” 著: 透析膜の生体適合性 透析膜の素材はいかに関与するか,東京,東京医学社, pp. 4, 2010.
[63]内藤秀宗, “無抗凝固剤透析におよぼす中空糸内径の影響,”人工臓器, 14, pp. 42- 44, 1985.
[64] 竹沢真吾, “第 1 章 2 血液浄化療法の歴史,” 臨床工学講座 生体機能代行装置学血液浄化療法装置,東京,医歯薬出版株式会社, pp. 2-4, 2018.
[65] PR. Craddock, J. Feht, AP. Dalmasso, KL. Brigha, HS. Jacob, “Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes,” JCI, 59, pp. 879-888, 1977.
[66]江本正志,江本善子, “10 補体って何？補体にはどんな働きがあるの？,”ケアに役立つ！ナースのためのカンタン免疫学,東京,株式会社学研メディカル秀潤社, pp. 62-67, 2016.
[67] R. Hakim, R. Wingard, R. Parker, “Effect of the Dialysis Membrane in the Treatment of Patients with Acute Renal Failure,” N Engl J Med, 331, pp. 1338- 1342, 1994.
[68] 丹下佳洋, “第 1 章 血液浄化療法とは,”臨床工学講座 生体機能代行装置学 血液浄化療法装置,東京,医歯薬出版株式会社, pp. 1-8, 2019.
[69]勢能八郎, “ポリスルフォン膜の生体適合性,” 腎と透析, 55, pp. 130-134, 2003.
[70]峰島三千男, “血液浄化膜の選択,” 腎と透析, 83, pp. 404-409, 2017.
[71] 田中佑樹, 薬師一実,富田恵介, 野間啓太, 久門晶子,澤田正二,小山正樹,今田直樹, “前希釈オンラインHDFにおけるFIX-210 Secoの溶質除去能および生体適合性の評価,” 腎と透析別冊2016 HDF 療法'16, pp. 176-177, 2016.
[72] R. Selgas, F. Maduell, T. Tomo, “New biocompatible haemodiafiltration membrane to enable maximum substitution for sensitive patients,” EMJ Nephrol, 5, pp. 43-50, 2017.
[73]斎藤明, “ダイアライザーと滅菌,”人工臓器, 18, 1989.
[74] 錦織伸司, 井関慧,永田光葉, 藤原哲,渡部尚人,安達恭子,杉原克彦, 福間優太,福島成文,宮里恵美,山中英樹, 藤井義久, “膜素材と膜面積の異なる2 種類のhemofilterがlife-timeに及ぼす影響,”日本急性血液浄化学会雑誌, 8, pp. 63-67, 2017.
[75] 鎌野千佐子,大沢弘和,橋本和政,坂田沙弥子,山本美生,吉田秀光, 齋藤サビーネ京子,木嶋祥一郎,柏木哲也, 飯野靖彦, 片山泰朗, “ポリスルホン膜 FPXによる血小板数減少が示唆された維持血液透析患者-2 症例の報告-,” 透析会誌, 42, pp. 573-580, 2009.
[76] H. Spijker, R. Graaff, P. Boonstra, H. Busscher, W. van Oeveren, “On the influence of flow conditions and wettability on blood material interactions,” Biomaterials, 24, pp. 4717-4727, 2003.
[77] R. Hakim, P. Held, D. Stannard, “Effect of the dialysis membrane on mortality of chronic hemodialysis patients,” Kidney Int, 50, pp. 566-570, 1996.
[78] T. Mizuno, T. Tsukiya, Y. Takewa, E. Tatsumi, “Differences in clotting parameters between species for preclinical large animal studies of cardiovascular devices,” J Artif Organs, 21, pp. 138-141, 2018.
[79] 砂子澤裕, “第 3 章 腎機能検査,” 著: 臨床工学講座 生体機能代行装置学 血液浄化療法装置,東京,医歯薬出版株式会社, pp. 17-28, 2018.
[80] M. Gawaz, S. Mujais, B. Schmidt, H. Gurland, “Platelet-leukocyte aggregation during hemodialysis,” Kidney Int, 46, pp. 489-495, 1994.
[81] M. Savobic, B. Salobir, Z. I. Prelosnik, P. Bratina, V. Bojec, P. J. Buturovic, “The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis,” Pathophysiol Haemost Thromb, 34, pp. 274-278, 2005.
[82] S. Hidaka, “Hydrophilic Polymer-Coated Polysulfone Membrane Improves Endothelial Function of Hemodialysis Patients A Pilot Study,” J Clin Nephrol Res, 2, 2015.
[83] 角田奈々絵,小久保健一, 酒井清隆, 福田誠,宮崎誠,日吉辰夫, “再生セルロースの透析膜の粗面粗さが抗血栓性に与える影響,”人工臓器, 27, pp. 475-479, 1998.
[84]武本佳昭, “細胞内Caイオン動態を指標とする新しい人工透析膜の生体適合性評価法の開発,”人工臓器, 18, pp. 1185-1190, 1989.
[85] T. Yamaka, K. Ichikawa, M. Saito, K. Watanabe, A. Nakai, N. Higuchi, N. Igarashi, H. Yoshimoto, “Biocompatibility of the new anticoagulant dialyzer TORAYLIGHT ® NV,” Science Postprint, WEB ONLY, 2014.
[86] K. Namekawa, M. Fukuda, M. Matsuda, Y. Yagi, K. Yamamoto, K. Sakai, “Nanotechnological characterization of human serum albumin adsorption on wet synthetic polymer dialysis membrane surfaces,” ASAIO J, 55, 2009.
[87]川端研治, “血液透析治療の生体適合性評価,” 透析会誌, 38, pp. 1621-1627, 2005.
[88] M. Mascelli, S. Worley, N. Veriabo, “Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPⅡb/Ⅲa therapy,” Circulation, 96, pp. 3860-3866, 1997.
[89]武本佳昭, 長沼俊秀,吉村力勇, “生体適合性の指標,”透析膜の生体適合性,東京,東京医学社, pp. 9-15, 2010.
[90]川西秀樹, “生体適合性とは,”透析膜の生体適合性,東京,東京医学社, pp. 1-8, 2010.
[91] AC. Yamashita, T. Ono, N. Tomisawa, “Verification of physicochemical structures of dialysis membrane using reversal dialysis technique,” Hemodial Int, Suppl 2, pp. S3-S9, 2017.
[92]山中学, “血小板の形態と機能,” 血液と脈管, 5, pp. 445-453, 1974.
[93] T. Mueller, M. Seitz, I. Eckle, “Biocompatibility differences with respect to the dialyzer sterilization method,” Nephron 1998, pp. 139-142, 1998.
[94] H. Shintani, A. Nakamura, “Formation of 4, 4'-methylenedianiline in polyurethane potting materials by either gamma ray ro autoclave sterilization,” J Biomed Mater Res, 25, pp. 1275-1286, 1991.
[95] M. Posadas, D. Hahn, W. Schleuter, J. Paparello, “Thrombocytopenia associated with dialysis treatments,” Hemodial Int, 15, pp. 416-423, 2011.
[96] L. De Prada, J. Lee, A. Gillespie, J. Benjamin, “Thrombocytopenia associated with one type of polysulfone hemodialysis membrane: a report of 5 cases,” Am J Kidney Dis, 61, pp. 131-133, 2013.
[97] V. Filiopoulos, N. Manolios, D. Vlassopoulos, “Use of electron-beam sterilized hemodialysis membranes is not associated with significant,” Int J Artif Organs , 36, pp. 217-219, 2013.
[98] S. Liu, W. Shi, X. Liang, Y. Su, Y. Liang, B. Zhang, Z. Ye, L. Xu, Y. Xia, C. He, J. Ma, Y. Tao, H. Ye, H. Li, “Cellulose triacetate dialyzer reduces platelet loss during continuous veno-venous hemofiltration,” Blood Purif, 29, pp. 375-382, 2010.
[99] S. Stefoni, L. Coil, G. Cianciolo, G. Donati, G. Ruggeri, E. Ramazzotti, R. Pohlmeier, D. Lang, “Inflammatory response of a new synthetic dialyzer membrane. A randomised cross-over comparison between polysulfone and helixone,” Int J Artif Organs, 26, pp. 26-32, 2003.
[100] LB. De Sanctis, S. Stefoni, G. Cianciolo, L. Coil, A. Buscaroli, G. Feliciangeli, LC. Borgnino, M. Bonetti, MC. Gregorini, P. De Giovanni, R. Buttazzi, “Effect of different dialysis membranes on platelet function. A tool for biocompatibility evaluation,” Int J Artif Organs, 19, pp. 404-410, 1996.
[101]山下文子, “ポリスルホン膜の滅菌の違いは抗血栓性に影響を与え得るか,”日本血液浄化技術学会会誌, 20, pp. 75-78, 2012.
[102]滑川亘希,松田雅人,山本健一郎, 福田誠, 酒井清孝, “透析膜の表面特性と蛋白質吸着,”透析膜の生体適合性,東京,東京医学社, p. 16-26, 2010.
[103] H. Yasuda, K. Sekine, T. Abe, S. Suzaki, A. Katsumi, N. Harada, H. Higashi, Y. Kishihara, H. Suzuki, T. Takebayashi, “Comparison of two polysulfone membranes for continuous renal replacement therapy for sepsis: a prospective cross-over study,” Renal Replacement Therapy, 4, 2018.
[104] J. Vienken, M. Diamantoglou, C. Hahn, H. Kamusewitz, D. Paul, “Considerations on developmental aspects of biocompatible dialysis membranes,” Artif Organs , 19, pp. 398-406, 1995.
[105] M. Hayama, K. Yamamoto, F. Kohori, T. Uesaka, Y. Ueno, H. Sugaya, I. Itagaki, K. Sakai, “Nanoscopic behavior of polyvinylpyrrolidone particles on polysulfone/polyvinylpyrrolidone film,” Biomaterials, 25, pp. 1019-1028, 2004.
[106] M. Miyata, S. Konishi, Y. Shimamoto, A. Kamada, K. Umimoto, “Influence of Sterilization and Storage Period on Elution of Polyvinylpyrrolidone from Wet- Type Polysulfone Membrane Dialyzers,” ASAIO J, 61, pp. 468-473, 2015.
[107] M. Siebeck, T. Dimski, T. Brandenburger, T. Slowinski, D. Kindgen-Milles, “Super High-Flux Continuous Venovenous Hemodialysis Using Regional Citrate Anticoagulation: Long-Term Stability of Middle Molecule Clearance,” Ther Apher Dial, 22, pp. 355-364, 2018.
[108] Y. Yoshimoto, “Kinetics of anticoagulant binding to continuous hemofilter membranes,” J Artif Organs, 5, pp. 136-140, 2002.
[109] A. Lorenzin, F. Garzotto, A. Alghisi, M. Neri, D. Galeano, S. Aresu, A. Pani, E. Vidal, Z. Ricci, L. Murer, S. Goldstein, C. Ronco, “CVVHD treatment with CARPEDIEM: small solute clearance at different blood and dialysate flows with three different surface area filter configurations,” Pediatr Nephrol, 31, pp. 1659-1665, 2016.
[110]塚本功,村杉浩,秋元照美,土持多美恵,仲松晋也,山下芳久,正田純子,菅原壮一,鈴木洋通, “CHDF施行時におけるhemofilterの凝固系への影響,” ICUとCCU, 32, pp. S128-132, 2008.
[111] 畑中美博, “ポリスルホン製持続緩徐式血液液濾過器「エクセルフロー」の特長,” ICUとCCU, 32, pp. S146-151, 2008.
[112]松田真太郎, “持続的腎機能代替療法におけるポリエーテルスルフォン膜およびポリスルフォン膜 hemofilterに対するhemofilter life-timeに関する検討,”日本血液浄化技術学会会誌, 21, pp. 387-389, 2013.
[113] N. Tomisawa, AC. Yamashita, “Filtration and Adsorption of Adsorption of Albumin in Commercial Hemofilters,” J. Chem. Eng. Japan, 43, pp. 521-528, 2010.
[114] AC. Yamashita, N. Tomisawa, “Importance of membrane materials for blood purification devices in critical care,” Transfusion and Apheresis Science, 40, pp. 23-31, 2009.
[115] T. Nakada, S. Oda, K. Matsuda, “Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock,” Mol Med, 14, pp. 257-263, 2008.
[116] S. Goto, S. Ookawa, A. Saito, “Differences in the adsorption of nafamostat mesilate between polyester-polymer alloy and polysulfone membranes,” J Artif Organs, 20, pp. 138-144, 2017.
[117] 甲田豊, “10 章 HDFと生体適合性,” HDF 療法ハンドブック,東京,南江堂, pp. 99-109, 2000.
[118]桃谷伸二, “ニプロ持続緩徐式血液濾過器「UTフィルター」について,” ICUとCCU, 32, pp. S153-S155, 2008.
[119] 稲垣王子, 西庵良彦, 中川清彦, 中西裕治,孝光義博, 藤田嘉一, “陽イオン, 陰イオン染料による透析膜荷電性の評価,”人工臓器, 21, pp. 942-945, 1992.
[120]山下明泰, “CRRTのフィルター性能と選択―膜の吸着能を考慮した浄化器の評価,”医学のあゆみ, 245, pp. 285-291, 2013.
[121] C. Ronco, A. Brendolan, A. Lupi, G. Metry, N. Levin, “Effects of a reduced inner diameter of hollow fibers in hemodialyzers,” Kidney Int, 58, pp. 809-817, 2000.
[122]峰島三千男, 血液浄化器 性能評価の基礎,東京:日本メディカルセンター, pp. 56-77, 2002.
[123]東レメディカル株式会社, HEMOFEEL SHG,東京:東レメディカル株式会社,カタログ.
[124] 野村晃司, “フィブリノゲン,” JapanKnowledge Lib, Available: https://japanknowledge.com/lib/display/?lid=1001000305946. [アクセス日: 25 11 2019].
[125] M. Hayama, K. Yamamoto, F. Kohori K. Sakai, “How polysulfone dialysis membranes containing polyvinylpyrrolidone achieve excellent biocompatibility?,” J MEMBRANE SCI, 234, pp. 41-49, 2004.
[126] K. Togo, M. Yamamoto, M. Imai, K. Akiyama, A. Yamashita, “Comparison of biocompatibility in cellulose triacetate dialysis membranes with homogeneous and asymmetric structures,” Renal Replacement Therapy, 4, 2018.
[127] K. Togo, M. Yamamoto, T. Ono, M. Imai, K. Akiyama, K. Ebine , Y. AC, “Comparison of biocompatibility in polysulfone dialysis membranes with different sterilization,” Hemodial Int, 22, pp. S10-S14, 2018.
[128] Y. Endo, S. Mamiya, M. Satoh, K. Takahashi, T. Harada, “Plasma β- Thromboglobulin and Platelet Factor 4 in Patients with Chronic Renal Failure and Effect of Hemodialysis,” Tohoku J. exp. Med, 135, pp. 349-358, 1981.
[129] M. Broman, B. Frenckner, A. Bjällmark, M. Broomé, “Recirculation during veno-venous extra-corporeal membrane oxygenation - a simulation study,” Int J Artif Organs, 38, pp. 23-30, 2015.
[130] F. Keller, J. Seemann, L. Preuschof, G. Offermann, “Risk factors of system clotting in heparin-free haemodialysis,” Nephrol Dial Transplant, 5, pp. 802- 807, 1990.
[131] A. Davenport, “The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit,” Am J Kidney Dis, 30 pp. S20-27, 1997.「
[132] I. Masakane, S. Esashi, A. Yoshida, T. Chiba, H. Fujieda, Y. Ueno, H. Sugaya, “A new polymethylmetacrylate membrane improves the membrane adhesion of blood components and clinical efficacy,” Renal Replacement Therapy, 3, 2017.
[133] I. Baldwin, “Factors affecting circuit patency and filter ‘life’,” Contrib Nephrol, 156, pp. 178-184, 2007.
[134]岩本祐介,安藤稔,土屋健, 二瓶宏, “透析患者の血小板減少症の解析,”日腎会誌, 41, pp. 712-718, 1999.
[135]北本康則, 牧野哲, 長井克敏, 阿部善治,扇谷博,残間保雄,太田美喜子, 二木源,田熊淑男, 上田仁, 門間弘道, 石崎允, 高橋寿, 関野宏, “血液透析患者の血小板凝集能について,” 透析会誌, 18, pp. 207-212, 1985.
論文の公開元へ
